Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF
Recruiting
Phase 3Interventional Study
Lupus NephritisSystemic Lupus Erythematosus (SLE)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
Ready to participate?
Review the details below, then apply to join this clinical trial.
At a Glance
Age
14 and older
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
196 (estimated)
Sponsor
Assistance Publique - Hôpitaux de Paris · Other
Who this trial is looking for
This trial is looking for children and adults with active lupus nephritis. Participants will receive either obinutuzumab with mycophenolate mofetil (MMF) or standard treatment with oral corticosteroids and MMF to see which is more effective.
Are You a Good Fit for This Trial?
You may be able to join if
I am a child aged 14-17 years old or an adult.
I have active lupus nephritis confirmed by a kidney biopsy within the last 8 weeks.
I have a urine protein-to-creatinine ratio of 0.5 g/g or higher.
I have no reasons preventing me from using the involved medications.
I can provide my consent to join this trial.
I am willing to use contraception while taking MMF.
You may not be able to join if
I have had a severe flare-up of my lupus requiring more medication than allowed.
I cannot be given 10 mg of prednisone after joining the study.
I am pregnant or breastfeeding.
I have used certain monoclonal antibodies in the last 6 months.
I have severe damage to my kidneys.
I have stage 4 or 5 chronic kidney disease.
I have an active infection like HIV or hepatitis.
I have had certain abnormal cervical conditions in the past 3 years.
Summarized in plain language from this trial's official eligibility criteria.
The full criteria are further down this page — only the research team can
confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
This is a randomised, open label, controlled non-inferiority phase III multicentre trial.
As primary objective, the study aims to demonstrate that a regimen free of additional oral corticosteroids but with obinutuzumab (and MMF) is non-inferior to a regimen based on oral corticosteroids and MMF in achieving the primary outcome of complete renal response at week 52 without receiving corticosteroid…
This is a randomised, open label, controlled non-inferiority phase III multicentre trial.
As primary objective, the study aims to demonstrate that a regimen free of additional oral corticosteroids but with obinutuzumab (and MMF) is non-inferior to a regimen based on oral corticosteroids and MMF in achieving the primary outcome of complete renal response at week 52 without receiving corticosteroids above a prespecified dose.
As secondary objectives, the study aims:
* To compare the efficacy of the treatments in both arms in terms of:
* partial plus complete renal response at week 52;
* proteinuria \< 0.8g/g at week 52;
* extrarenal flares;
* response as defined by a \>4 points reduction in SELENA-SLEDAI score at week 52.
* To compare the safety of the treatments in both arms in terms of occurrence of:
* toxicity of corticosteroids;
* serious Adverse Events;
* serious Infectious Episodes;
* new damage.
* To compare the number of patients with non-adherence to treatment in both arms.
* To estimate the efficiency of obinutuzumab in this indication.
The ancillary studies will allow:
* To implement a biobank (serum, plasma, DNA, cells and urine) and a bank of renal biopsies for studies that will be part of separate research funding bids (patients will be informed that their samples and data may be used for subsequent studies and offered to consent or not).
* To identify which target therapeutic levels of MMF best predicts response with least toxicity (ancillary study).
* To have long term data on renal function and damage.
Trial Locations
Loading…
Loading trial locations…
Facility
City
State
Country
Status
Eligibility Criteria
Inclusion Criteria:
* Children aged 14-17 years old and adults;
* Active lupus nephritis, as defined by kidney biopsy within the preceding 8 weeks, assessed by the International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification: class III or IV (A or A/C) ± V with active lesion…
Inclusion Criteria:
* Children aged 14-17 years old and adults;
* Active lupus nephritis, as defined by kidney biopsy within the preceding 8 weeks, assessed by the International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification: class III or IV (A or A/C) ± V with active lesions in at least 10% of the viable glomeruli;
* Urine protein-to-creatinine ratio (uPCR) ≥ 0.5 g/g at any time in the 14 days before inclusion;
* No contraindications to the use of IV methylprednisolone, MMF, oral corticosteroids or obinutuzumab;
* Ability to provide informed consent;
* Willingness to use appropriate contraception, as recommended when using MMF.
Exclusion Criteria:
* Severe "critical" SLE flare defined as any SLE manifestation requiring more immunosuppression than allowed in the protocol, in the physician's opinion;
* Patients who cannot be prescribed 10 mg prednisone corticosteroids "only", after inclusion according to the physician's opinion;
* Pregnant and breastfeeding woman;
* Prior use within 6 months of inclusion of therapeutic monoclonal antibody and/or B- or T cell modulating 'biologic' except belimumab that can be used up to 7 days before inclusion;
* Obsolescence of \>60% of the glomeruli or tubulointerstitial scarring of \>60%;
* CKD stage 4 or stage 5 defined as eGFR \<30 ml/min/1.73 m2 according to CKD-EPI (to be differentiated from acute renal injury);
* Active infections, including but not limited to human immunodeficiency virus (HIV), hepatitis B in the absence of a specific therapy, hepatitis C or tuberculosis;
* Receipt of a live-attenuated vaccine in the 4 weeks prior to study enrolment;
* History of cervical dysplasia CIN Grade III, cervical high-risk human papillomavirus or abnormal cervical cytology other than abnormal squamous cells of undetermined significance (ASCUS) in the past 3 years in female patients. However, the patient will be eligible in the following conditions: follow-up HPV test is negative or cervical abnormality was effectively treated \>1 year ago.
Picking one helps us show the most relevant trials first.
Your results are loading in the background — you can
change this any time from the results page.
Set your location to continue
Find My Trials uses your location to surface clinical trials near you.
Add your city or zip code to your profile and try again.
